Please assess the completion status of the following clinical trial:

Trial Title: Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study:~1. Male or non-pregnant female (if female, either post-menopausal, or if of child-bearing potential, using adequate contraception e.g. hormonal or barrier methods, or surgically sterile, and not lactating)~2. Age \>/= 18 years of age~3. Present or prior history of symptoms of heart failure (dyspnea, fatigue) consistent with diagnosis of diastolic heart failure, following optimized medical therapy including blood pressure control with ACE inhibitors and/or beta-blockers for 2 weeks or over.~4. Echocardiographic evidence of preserved left ventricular systolic function (LVEF \>/= 45%) and evidence of diastolic dysfunction (by transmitral inflow, pulmonary venous flow, color M-mode and/or tissue Doppler).~5. Signed informed consent~Exclusion Criteria:~The presence of any of the following will exclude a patient from study enrollment:~1. Unwilling to participate for the 9-month duration of the study~2. Significant primary valvular, pulmonary or congenital cardiac disease believed to be the cause of dyspnea~3. Life expectancy or planned cardiac transplantation \<9 months~4. History of hypertrophic obstructive cardiomyopathy~5. Unstable angina or ischemia requiring revascularization~6. Renal insufficiency (Cr \>2.0 mg/dL in males and \>1.8 mg/dl in females, or modified Cockcroft-Gault estimate of creatinine clearance \<30 mL/min) at enrollment~7. Known hypersensitivity to spironolactone or eplerenone~8. Decompensated heart failure or clinical evidence of instability at the time of enrollment 9 History of hyperkalemia (\>6.0 mg/dL) with spironolactone~10. Use of spironolactone or amiloride within 30 days 11. Poorly controlled seating blood pressure at the time of drug initiation:~* Systolic blood pressure \>160 mmHg; and/or~* Diastolic blood pressure \>100 mmHg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eplerenone (Type: ACTIVE_COMPARATOR): Eplerenone 25mg daily for 2 weeks Titrated to Eplerenone 50mg daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo dosed daily

Based on this trial design, predict the completion outcome and termination type (if applicable).